Medicine
Defencath 3000 units/40.5 mg per 3 mL solution
Defencath 3000 units/40.5 mg per 3 mL solution is a prescription medicine containing Heparin and Taurolidine for intraluminal use, marketed by CorMedix, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. DEFENCATH vials must be stored at a controlled room temperature…
Key facts
- Active ingredient (INN)
- Heparin and Taurolidine
- Brand
- Defencath
- Strength
- 3000 units/40.5 mg per 3 mL
- Dosage form
- Solution
- Route
- Intraluminal
- Packs
- 10 vials
- Marketing authorisation holder
- CorMedix
- Manufacturer
- CorMedix
- Origin register
- US FDA, United States
- Storage
- Do not freeze. DEFENCATH vials must be stored at a controlled room temperature of 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F). DEFENCATH vials must be stored in the commercial carton, prior to the instillation in central venous catheters.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 April 2024
- Identifiers
- RxCUI 2670461, 2670468, 2670471 +1DailyMed set ID 13b3a61e-5a4b-4afb-8fa1-d76ebdb344d6NDC 72990-103Application NDA214520
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial, single-dose in 1 carton / 3 mL in 1 vial, single-dose | 72990-103-10 | CorMedix | 9 April 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 November 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Heparin and Taurolidine is a fixed-dose combination of an anti-coagulant and an unfractionated heparin. It is available as solution for intraluminal use. MedsAcross supplies Heparin and Taurolidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Heparin and TaurolidineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- DEFENCATH prescribing information (CorMedix) · U.S. National Library of Medicine, DailyMed
Need Defencath 3000 units/40.5 mg per 3 mL solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.